Literature DB >> 7702029

Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis.

B C Portal1, M J Richard, H S Faure, A J Hadjian, A E Favier.   

Abstract

Cystic fibrosis often combines an infectious pathology with a syndrome of malabsorption, both potentially capable of favoring the deleterious effects of reactive oxygen species. This study was a simultaneous evaluation of the main antioxidant systems dependent on micronutrients and of lipid peroxidation products in 27 children with cystic fibrosis and 17 healthy children. Plasma of cystic fibrosis patients showed very low concentrations of beta-carotene (0.30 +/- 0.2 vs 1.63 +/- 0.5 mumol/g cholesterol, P < 0.0001) and a lower activity of selenium-dependent glutathione peroxidase (263.6 +/- 42 vs 296.9 +/- 57 U/L, P = 0.028). In parallel, the higher plasma concentrations of organic hydroperoxides (171.5 +/- 54.4 vs 122.6 +/- 23.3 mumol/L, P = 0.001) and of thiobarbituric acid reactants (2.9 +/- 0.6 vs 2.4 +/- 0.3 mumol/L, P = 0.004) reflected oxidative stress in this pathology. In addition, in these patients the major substrates of lipoperoxidation were significantly lower, whether they be linoleic acid (2.26 +/- 0.8 vs 3.60 +/- 0.9 mmol/L, P < 0.0001) or arachidonic acid (0.55 +/- 0.2 vs 0.74 +/- 0.2 mmol/L, P = 0.006). These results suggested that nutritional deficiencies resulting from malabsorption could considerably amplify disorders related to toxicity of reactive oxygen species. These nutritional deficits could also be aggravated by the destruction of antioxidant compounds by the inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702029     DOI: 10.1093/ajcn/61.4.843

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  16 in total

Review 1.  The role of vitamins in cystic fibrosis.

Authors:  S B Carr; J McBratney
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  Pulmonary oxidative stress response in young children with cystic fibrosis.

Authors:  J Hull; P Vervaart; K Grimwood; P Phelan
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

3.  Increased carbon monoxide in exhaled air of patients with cystic fibrosis.

Authors:  P Paredi; P L Shah; P Montuschi; P Sullivan; M E Hodson; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

4.  Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.

Authors:  J Hull; A H Thomson
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

5.  Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis.

Authors:  C E Collins; P Quaggiotto; L Wood; E V O'Loughlin; R L Henry; M L Garg
Journal:  Lipids       Date:  1999-06       Impact factor: 1.880

6.  Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis.

Authors:  S Renner; R Rath; P Rust; S Lehr; T Frischer; I Elmadfa; I Eichler
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

7.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003.

Authors:  André M Cantin; Terry B White; Carroll E Cross; Henry Jay Forman; Ronald J Sokol; Drucy Borowitz
Journal:  Free Radic Biol Med       Date:  2006-09-29       Impact factor: 7.376

8.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 9.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

10.  Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis.

Authors:  J E Freedman; J Loscalzo; S E Benoit; C R Valeri; M R Barnard; A D Michelson
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.